ArticleJournal of thoracic disease2026
Gastroesophageal reflux disease predicts 6-month readmission in acute exacerbation of chronic obstructive pulmonary disease: development and validation of a nomogram.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, and acute exacerbation of COPD (AECOPD) frequently leads to hospitalisation and early readmission. Gastroesophageal reflux disease (GERD) is a common comorbidity in COPD, but its role in predicting post-discharge readmission remains unclear. This study aimed to investigate the impact of GERD on the risk of 6-month readmission in patients with AECOPD and to develop an individualized predictive nomogram model. Methods: A total of 683 patients with AECOPD admitted to the Department of Respiratory Medicine, Anhui No. 2 Provincial People's Hospital, between May 2023 and March 2025 were prospectively enrolled. GERD was assessed using the GERD Questionnaire, with a total score of ≥8 used as the diagnostic cutoff. All patients were followed up for 6 months after discharge. Regression analyses were performed to identify predictors and develop a nomogram, followed by internal validation. Results: Among the 683 enrolled patients, the overall 6-month readmission rate was 29.6% (202/683). Multivariate logistic regression analysis showed that acute exacerbation in previous 1 year [odds ratio (OR) =1.629; 95% confidence interval (CI): 1.035-2.563; P=0.03], GERD (OR =2.553; 95% CI: 1.616-4.033; P<0.001), Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage (OR =1.365; 95% CI: 1.097-1.697; P=0.005), and B-type natriuretic peptide (BNP) (OR =1.008; 95% CI: 1.002-1.014; P=0.006) were independent risk factors for readmission within 6 months after discharge for AECOPD patients, while body mass index (BMI) (OR =0.875; 95% CI: 0.814-0.940; P<0.001) was a protective factor. The model demonstrated moderate discriminative ability, with an area under the curve (AUC) of 0.708 (95% CI: 0.653-0.758) in the training group and 0.731 (95% CI: 0.648-0.784) in the validation group. The calibration curve demonstrated good model fit, and decision curve analysis confirmed that the model had clinical utility within the threshold range of 0.2 to 0.6. Conclusions: A prediction model based on five clinically accessible variables-BMI, acute exacerbation in previous 1 year, GERD, GOLD stage, and BNP-can effectively identify patients at high risk for readmission within 6 months following discharge for AECOPD. This finding suggests that GERD is an important predictor of readmission in AECOPD patients following discharge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.